241.43
price up icon1.12%   2.67
after-market Handel nachbörslich: 236.77 -4.66 -1.93%
loading
Schlusskurs vom Vortag:
$238.76
Offen:
$238.2
24-Stunden-Volumen:
171.47K
Relative Volume:
0.34
Marktkapitalisierung:
$311.50B
Einnahmen:
$3.81B
Nettoeinkommen (Verlust:
$-644.79M
KGV:
-38.69
EPS:
-6.24
Netto-Cashflow:
$-669.77M
1W Leistung:
+5.71%
1M Leistung:
-3.09%
6M Leistung:
+0.00%
1J Leistung:
+0.00%
1-Tages-Spanne:
Value
$237.13
$242.94
1-Wochen-Bereich:
Value
$228.93
$242.94
52-Wochen-Spanne:
Value
$172.67
$287.88

Beigene Ltd Adr Stock (ONC) Company Profile

Name
Firmenname
Beigene Ltd Adr
Name
Telefon
13459494123
Name
Adresse
C/O MOURANT GOVERNANCE SERVICES (CAYMAN), GRAND CAYMAN
Name
Mitarbeiter
11,000
Name
Twitter
Name
Nächster Verdiensttermin
Name
Neueste SEC-Einreichungen
Name
ONC's Discussions on Twitter

Vergleichen Sie ONC mit anderen Aktien

Aktien Preis Marktkapitalisierung Umsatz Nettogewinn Free Cashflow ENV
Biotechnology icon
ONC
Beigene Ltd Adr
241.43 24.41B 3.81B -644.79M -669.77M -6.24
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
436.00 111.55B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
AKTX
Akari Therapeutics Plc Adr
1.335 42.47M 0 0 0 0.00
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
588.34 63.16B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
VRNA
Verona Pharma Plc Adr
75.06 5.92B 0 -153.72M -103.81M -2.00

Beigene Ltd Adr Stock (ONC) Upgrades & Downgrades

Datum Aktion Analytiker Ratingänderung
2025-04-07 Eingeleitet RBC Capital Mkts Outperform
2025-03-03 Hochstufung BofA Securities Neutral → Buy
2024-12-03 Fortgesetzt Morgan Stanley Overweight
2024-09-18 Eingeleitet JMP Securities Mkt Outperform
2024-02-06 Fortgesetzt JP Morgan Overweight
2023-09-12 Eingeleitet Macquarie Outperform
2023-08-17 Eingeleitet Jefferies Buy
2023-07-17 Eingeleitet Citigroup Buy
2023-06-30 Herabstufung Bernstein Outperform → Mkt Perform
2023-01-12 Eingeleitet Daiwa Securities Buy
2022-10-13 Hochstufung Guggenheim Neutral → Buy
2022-10-13 Hochstufung SVB Leerink Mkt Perform → Outperform
2022-08-09 Fortgesetzt JP Morgan Overweight
2022-03-17 Herabstufung SVB Leerink Outperform → Mkt Perform
2022-02-07 Eingeleitet Deutsche Bank Buy
2021-10-12 Eingeleitet Bernstein Outperform
2021-10-06 Hochstufung CLSA Underperform → Buy
2021-03-08 Eingeleitet China Renaissance Buy
2021-03-01 Herabstufung CLSA Outperform → Underperform
2020-11-09 Herabstufung Ladenburg Thalmann Buy → Neutral
2020-11-06 Herabstufung Maxim Group Buy → Hold
2020-11-06 Herabstufung Piper Sandler Neutral → Underweight
Alle ansehen

Beigene Ltd Adr Aktie (ONC) Neueste Nachrichten

pulisher
May 21, 2025

BeiGene Shareholders Approve Director Elections and Auditors By Investing.com - Investing.com India

May 21, 2025
pulisher
May 13, 2025

Daiwa Sees Limited Upside for HSI, Prefers HK Stocks w/ Tech Trading Opportunities Like BEIGENE - AASTOCKS.com

May 13, 2025
pulisher
May 12, 2025

Blood Cancer Treatment Market Sees Accelerated Growth Across the 7MM Amid Rising Incidence and Breakthroughs | DelveInsight - GlobeNewswire Inc.

May 12, 2025
pulisher
May 08, 2025

Market Momentum: BeiGene Ltd. ADR (ONC) Registers a -3.93 Decrease, Closing at 232.25 - DWinneX

May 08, 2025
pulisher
May 07, 2025

BeiGene shares tumble over 5% as Q1 revenue misses estimates - Investing.com

May 07, 2025
pulisher
May 07, 2025

BeiGene shares tumble over 5% as Q1 revenue misses estimates By Investing.com - Investing.com South Africa

May 07, 2025
pulisher
Apr 29, 2025

BeiGene wins patent challenge against Pharmacyclics By Investing.com - Investing.com India

Apr 29, 2025
pulisher
Apr 29, 2025

BeiGene wins patent challenge against Pharmacyclics - Investing.com

Apr 29, 2025
pulisher
Apr 29, 2025

BeiGene wins US patent dispute over cancer drug By Investing.com - Investing.com India

Apr 29, 2025
pulisher
Apr 29, 2025

BeiGene wins US patent dispute over cancer drug - Investing.com

Apr 29, 2025
pulisher
Apr 28, 2025

BeiGene reports financial results under PRC GAAP By Investing.com - Investing.com South Africa

Apr 28, 2025
pulisher
Apr 28, 2025

BeiGene reports financial results under PRC GAAP - Investing.com

Apr 28, 2025
pulisher
Apr 27, 2025

Press Release Distribution & PR Platform - ACCESS Newswire

Apr 27, 2025
pulisher
Apr 24, 2025

Is First Trust NYSE Arca Biotechnology ETF (FBT) a Strong ETF Right Now? - Yahoo Finance

Apr 24, 2025
pulisher
Apr 21, 2025

BigBear.ai Holdings Inc (BBAI) gets rating Downgrade from Northland Capital - knoxdaily.com

Apr 21, 2025
pulisher
Apr 21, 2025

Morgan Stanley analysts upgrades an Equal-weight rating for Urban Edge Properties (UE) - knoxdaily.com

Apr 21, 2025
pulisher
Apr 21, 2025

RBC Capital Mkts initates BeiGene Ltd. ADR (ONC) rating to an Outperform - knoxdaily.com

Apr 21, 2025
pulisher
Apr 17, 2025

BGNE Page Not Found - Benzinga

Apr 17, 2025
pulisher
Apr 16, 2025

Beigene’s Wang Xiaodong sells $10.1m in stock By Investing.com - Investing.com India

Apr 16, 2025
pulisher
Apr 16, 2025

Beigene’s Wang Xiaodong sells $10.1m in stock - Investing.com

Apr 16, 2025
pulisher
Apr 16, 2025

Should You Invest in the First Trust NYSE Arca Biotechnology ETF (FBT)? - Yahoo Finance

Apr 16, 2025
pulisher
Apr 10, 2025

Permian Resources Corp [PR] Director makes an insider purchase of 250,000 shares worth 3.02 million. - knoxdaily.com

Apr 10, 2025
pulisher
Apr 07, 2025

RBC Capital sets BeiGene stock Outperform with $312 target By Investing.com - Investing.com South Africa

Apr 07, 2025
pulisher
Apr 07, 2025

RBC Capital sets BeiGene stock Outperform with $312 target - Investing.com

Apr 07, 2025
pulisher
Apr 04, 2025

JMP reiterates BeiGene stock with $348 target despite trial halt - Investing.com India

Apr 04, 2025
pulisher
Apr 03, 2025

Beigene’s president Wu Xiaobin sells $14.6 million in shares - Investing.com

Apr 03, 2025
pulisher
Apr 03, 2025

Beigene’s president Wu Xiaobin sells $14.6 million in shares By Investing.com - Investing.com India

Apr 03, 2025
pulisher
Mar 31, 2025

Macquarie Prefers Biotechs Over CDMOs; Top Picks BEIGENE/ AKESO - AASTOCKS.com

Mar 31, 2025
pulisher
Mar 20, 2025

Beigene director Wang Xiaodong sells $10.9 million in shares By Investing.com - Investing.com South Africa

Mar 20, 2025
pulisher
Mar 20, 2025

Beigene director Wang Xiaodong sells $10.9 million in shares - Investing.com India

Mar 20, 2025
pulisher
Mar 18, 2025

Beigene’s Wu Xiaobin anticipates $1.06 million from RMB shares sale - Investing.com

Mar 18, 2025
pulisher
Mar 13, 2025

Bernstein raises BeiGene stock price target to $259 - Investing.com

Mar 13, 2025
pulisher
Mar 12, 2025

BeiGene CEO John Oyler sells $10 million in shares - Investing.com India

Mar 12, 2025
pulisher
Mar 08, 2025

Beigene CEO John Oyler sells $10.39 million in shares By Investing.com - Investing.com South Africa

Mar 08, 2025
pulisher
Mar 08, 2025

Beigene CEO John Oyler sells shares worth $14.6 million - Investing.com India

Mar 08, 2025
pulisher
Mar 08, 2025

BeiGene Stock: Top Executives Sell Shares Near Record High - Sharewise

Mar 08, 2025
pulisher
Mar 07, 2025

Beigene CEO John Oyler sells shares worth $14.6 million By Investing.com - Investing.com South Africa

Mar 07, 2025
pulisher
Mar 07, 2025

Beigene CEO John Oyler sells $10.39 million in shares - Investing.com

Mar 07, 2025
pulisher
Mar 07, 2025

BeiGene Ltd. Sponsored ADR to Host Earnings Call - ACCESS Newswire

Mar 07, 2025
pulisher
Mar 06, 2025

Beigene chair Wang Xiaodong sells shares worth over $2 million - Investing.com India

Mar 06, 2025
pulisher
Mar 04, 2025

Beigene president sells economic interest in RMB shares for $1.16 million - Investing.com India

Mar 04, 2025
pulisher
Mar 04, 2025

BOCOMI: BEIGENE (06160.HK) Guides to Positive 2025 Operating Profit; Rating Kept at Buy - AASTOCKS.com

Mar 04, 2025
pulisher
Mar 03, 2025

JPMorgan maintains BeiGene stock Overweight rating, $311 target - Investing.com India

Mar 03, 2025
pulisher
Mar 03, 2025

Beigene SVP sells $331,375 in American depositary shares By Investing.com - Investing.com South Africa

Mar 03, 2025
pulisher
Mar 03, 2025

Beigene SVP sells $331,375 in American depositary shares - Investing.com India

Mar 03, 2025
pulisher
Mar 03, 2025

JPMorgan maintains BeiGene stock Overweight rating, $311 target By Investing.com - Investing.com South Africa

Mar 03, 2025

Finanzdaten der Beigene Ltd Adr-Aktie (ONC)

Umsatz

loading

Nettogewinn

loading

Free Cashflow

loading

ENV

loading

Beigene Ltd Adr-Aktie (ONC) Insiderhandel

Insiderhandel Beziehung Datum Transaktion Kosten #Aktien Wert ($) #Aktien Gesamt
Wang Xiaodong
Chair, Scientific Advisory Brd
May 13 '25
Sale
223.50
41,760
9,333,272
0
OYLER JOHN
Chief Executive Officer
May 09 '25
Option Exercise
0.50
4,055,415
2,027,708
10,154,040
Wang Xiaodong
Chair, Scientific Advisory Brd
Apr 14 '25
Option Exercise
6.50
41,760
271,440
41,760
Wang Xiaodong
Chair, Scientific Advisory Brd
Apr 14 '25
Sale
242.66
41,760
10,133,595
0
$436.00
price up icon 0.45%
$1.335
price up icon 6.39%
$588.34
price down icon 1.43%
$75.06
price up icon 3.26%
$4.25
price up icon 0.48%
Kapitalisierung:     |  Volumen (24h):